Trametinib (GSK1120212) is an oral, reversible and selective allosteric inhibitor of MEK1/2 and is FDA-approved for the treatment of metastatic BRAFV600E mutant NSCLC and melanoma, in combination with BRAF inhibitors [7, 8]. Here, BRAF is linked to melanoma.